Related Experiment Videos
Acute generalized exanthematous pustulosis induced by bleomycin and confirmed by patch testing
A Altaykan1, G Boztepe, G Erkin
1Department of Dermatology, Hacettepe University Faculty of Medicine, Ankara, Turkey. draltaykan@yahoo.com.
The Journal of Dermatological Treatment
|March 15, 2005
Summary
Acute generalized exanthematous pustulosis (AGEP) is a severe drug reaction. This report details the first known case of AGEP caused by bleomycin, confirmed by patch testing.
Area of Science:
- Dermatology
- Toxicology
- Pharmacology
Background:
- Acute generalized exanthematous pustulosis (AGEP) is a severe cutaneous adverse drug reaction.
- It is characterized by widespread small sterile pustules on an erythematous background.
- Drugs are implicated in approximately 90% of AGEP cases.
Observation:
- A case of AGEP following bleomycin treatment is presented.
- Bleomycin is an antineoplastic agent used in chemotherapy.
- This represents the first reported instance of bleomycin-induced AGEP.
Findings:
- The diagnosis of AGEP was confirmed in the patient.
- Patch testing with bleomycin was positive, establishing a causal link.
- This finding highlights a previously unrecognized adverse drug reaction.
Implications:
- Clinicians should consider bleomycin as a potential cause of AGEP.
- This expands the spectrum of known drug triggers for AGEP.
- Further investigation into bleomycin hypersensitivity is warranted.